Table 2.

Results of univariate analysis for progression-free survival and disease-specific mortality in patients with neuroendocrine tumors

	Progression-free survival			Disease-specific mortality
Variable	HR	95% CI	P value	HR	95% CI	P value
Female	1·1	0·6 – 2·0	0·7	1·7	0·5 – 5·8	0·4
PNET vs. other subtypes	0·7	0·4 – 1·2	0·2	0·9	0·3 – 3·1	0·9
WHO 2010 grade G3 vs. G1/G2	1·2	0·2 – 8·9	0·8	66·5	6·0 – 743·0	0·001
Presence vs. absence of metastases
Liver	2·0	1·1 – 3·7	0·03	6·3	1·4 – 29·4	0·02
Lymph nodes	1·5	0·8 – 2·8	0·2	5·4	1·2 – 25·0	0·03
Bone	2·7	1·5 – 4·8	0·001	4·9	1·5 – 16·1	0·009
Lung	0·6	0·2 – 1·9	0·4	1·3	0·2 – 10·5	0·8
Hereditary vs. sporadic	0·4	0·2 – 0·9	0·02	0·3	0·1 – 1·4	0·1
Functional vs. non-functional tumor	0·6	0·4 – 1·1	0·1	0·9	0·3 – 2·9	0·8
Treatment after inclusion
Surgery	1·5	0·8 – 2·8	0·3	0·4	0·04 – 2·8	0·3
Medical	2·4	1·3 – 4·5	0·006	0·9	0·2 – 3·1	0·8
PRRT/LDT	2·2	1·1 – 4·4	0·02	2·3	0·5 – 10·8	0·3
SUVmax ≥ 55.9+	1·0	0·6 – 1·8	0·9	0·6	0·2 – 1·9	0·4
Total 68Ga-DOTATATE volume ≥7.0 ml	2·4	1·2 – 4.9	0.02	NA*	NA	NA
Total 68Ga-DOTATATE volume ≥35.8 ml	1·4	0·8 – 2·5	0·2	12·5	2·7 – 57·7	0·001
Biochemical biomarkers
Elevated plasma NSE (>15 ng/mL)	2·2	1·02 – 4·7	0·04	3·6	0·6 – 21·0	0·1
Elevated plasma CGA (>73 ng/mL)	1·4	0·8 – 2·8	0·3	NA*	NA	NA
Elevated urinary 5HIAA (>8 mg/24h)	1·7	1·0 – 3·0	0·07	5·2	1·5 – 18·8	0·01

HR, hazard ratio; CI, confidence interval; PNET, pancreatic neuroendocrine tumors; WHO, World Health Organization; SSA, somatostatin analogues; PRRT, peptide receptor radionuclide therapy; LDT, liver-directed therapy; SUVmax, maximum standardized uptake value; NA, not applicable.

⁺Median values,

^*Cox regression analysis was not performed as one of the groups had no events.